Literature DB >> 32352179

Novel CTNND2-TERT fusion in a spindle cell liposarcoma.

Michael Occidental1, Guomiao Shen1, Xiaojun Feng1, Kelsey Zhu1, Kevin Kelly2, Qian Nie2, Honey V Reddi2, Eleftheria Lakiotaki3, Nora Athina Viniou4, Penelope Korkolopoulou3, Konstantinos Linos5,6, George Jour1,7.   

Abstract

Soft tissue tumors can be categorized molecularly into two categories: tumors which are known to have recurrent molecular alterations and tumors which do not have consistent recurrent molecular alterations or translocations. These "nontranslocation" associated sarcomas are clinically more aggressive than their more stable counterparts. However, recent advances in RNA sequencing have discovered recurrent novel fusions within the latter group, namely TERT-TRIO fusions. Furthermore, a recent report discovered this fusion in a spindle cell liposarcoma. Our case describes a novel fusion of CTNND2, a neighbor gene of TRIO, and TERT in a spindle cell liposarcoma, and provides further evidence that spindle cell liposarcoma should be a distinct entity from dedifferentiated liposarcoma.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  CTNND2; RNA sequencing; TERT; anchored multiplex PCR; gene fusion; spindle cell liposarcoma

Mesh:

Substances:

Year:  2020        PMID: 32352179     DOI: 10.1002/gcc.22856

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  2 in total

1.  Case Report: Identification of Multiple TERT and FGFR2 Gene Fusions in a Pineal Region Glioblastoma Case.

Authors:  Xing Guo; Teng Chen; Shiming Chen; Chao Song; Dezhi Shan; Shujun Xu; Shuo Xu
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

2.  High prevalence of TERT aberrations in myxoid liposarcoma: TERT reactivation may play a crucial role in tumorigenesis.

Authors:  Junko Kunieda; Kyoko Yamashita; Yuki Togashi; Satoko Baba; Seiji Sakata; Kentaro Inamura; Keisuke Ae; Seiichi Matsumoto; Rikuo Machinami; Masanobu Kitagawa; Kengo Takeuchi
Journal:  Cancer Sci       Date:  2022-01-11       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.